Search

Displaying results 1711 - 1720 of 4212 in total
  1. Drug

    Betrixaban

    go.drugbank.com/drugs/DB12364
    Approved

    Betrixaban is a non-vitamin K oral anticoagulant whose action is driven by the competitive and reversible inhibition of the factor Xa [A7708]. … Betrixaban, now developed by Portola Pharmaceuticals Inc., is prescribed as a venous thromboembolism (VTE) prophylactic for adult patients with moderate to severe restricted motility or with other risks

  2. Drug

    Human papillomavirus type 11 L1 capsid protein antigen

    go.drugbank.com/drugs/DB10300
    ApprovedInvestigational

    It is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) types 6, 11, 16 and 18. … The vaccine is prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Types 6, 11, 16, and 18, which are produced by separate fermentations in recombinant *Saccharomyces

  3. Drug

    Human papillomavirus type 16 L1 capsid protein antigen

    go.drugbank.com/drugs/DB10301
    ApprovedInvestigational

    It is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) types 6, 11, 16 and 18. … The vaccine is prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Types 6, 11, 16, and 18, which are produced by separate fermentations in recombinant *Saccharomyces

  4. Drug

    Human papillomavirus type 18 L1 capsid protein antigen

    go.drugbank.com/drugs/DB10302
    ApprovedInvestigational

    It is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) types 6, 11, 16 and 18. … The vaccine is prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Types 6, 11, 16, and 18, which are produced by separate fermentations in recombinant *Saccharomyces

  5. Drug

    Olezarsen

    go.drugbank.com/drugs/DB18728
    ApprovedInvestigational

    [A264888] Olezarsen works to reduce the plasma triglyceride levels by reducing APOC3 production. … [L52033] On December 19, 2024, olezarsen was approved by the FDA for the treatment of familial chylomicronemia syndrome.[L52028] It is also being investigated for the treatment of hyperlipidemia.

  6. Drug

    Interferon alfacon-1

    go.drugbank.com/drugs/DB00069
    ApprovedWithdrawn

    Prior to final purification, Interferon alfacon-1 is allowed to oxidize to its native state, and its final purity is achieved by sequential passage over a series of chromatography columns. … Interferon alfacon-1 is produced in Escherichia coli (E. coli) cells that have been genetically altered by insertion of a synthetically constructed sequence that codes for Interferon alfacon-1.

  7. Drug

    Ondansetron

    go.drugbank.com/drugs/DB00904
    ApprovedInvestigationalWithdrawn

    Having been developed in the 1980s by GlaxoSmithKline and approved by the US FDA since January 1991, ondansetron has demonstrated a long history of use and efficacy. … It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.

  8. Drug

    Trofinetide

    go.drugbank.com/drugs/DB06045
    Approved

    [A258438] Trofinetide was approved by the FDA on March 10, 2023, for the treatment of Rett syndrome,[L45718,L45748] which is an X-linked neurodevelopmental disorder characterized by a range of cognitive … [A258438] Trofinetide is believed to work by reducing inflammation and apoptosis of neurons.

  9. Drug

    Bazedoxifene

    go.drugbank.com/drugs/DB06401
    ApprovedInvestigational

    Bazedoxifene is a third generation selective estrogen receptor modulator (SERM), developed by Pfizer following the completion of their takeover of Wyeth Pharmaceuticals. … In 2013, the combination product containing conjugated estrogens and bazedoxifene was approved by the FDA for the treatment of moderate to severe vasomotor symptoms associated with menopause, as well as

  10. Drug

    Human papillomavirus type 6 L1 capsid protein antigen

    go.drugbank.com/drugs/DB10299
    ApprovedInvestigational

    It is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) types 6, 11, 16 and 18. … The vaccine is prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Types 6, 11, 16, and 18, which are produced by separate fermentations in recombinant *Saccharomyces